PKU newborn screening aims to catch high phenylalanine right after birth. Tandem mass spectrometry flags blood phenylalanine levels above 2 mg/dL, with an overall sensitivity of 99.7% in large cohorts. False positives remain rare at under 0.05%, while classic PKU is confirmed when plasma phenylalanine exceeds 20 mg/dL.
Key Takeaways
- Newborn screening for PKU using tandem mass spectrometry detects Phe >2 mg/dL.
- Guthrie bacterial inhibition assay was first used for PKU screening in 1963.
- Universal newborn screening for PKU implemented in all 50 US states since 1966.
- In the United States, the incidence of phenylketonuria (PKU) is approximately 1 in 10,000 to 15,000 live births.
- Globally, PKU affects about 1 in 10,000 to 15,000 newborns, with variations by population.
- In Turkey, the incidence of PKU is one of the highest worldwide at 1 in 2,605 newborns.
- PKU is caused by mutations in the PAH gene on chromosome 12q22-q24.1.
- Over 1,100 different mutations in the PAH gene have been identified in PKU patients.
- The R408W mutation is the most common PAH variant, accounting for 20-30% in some populations.
- Musty odor in urine/sweat due to phenylacetate in 75% untreated.
- Eczematous rash seen in 20-30% of untreated infants with PKU.
- Seizures develop in 25% of untreated adolescents/adults with PKU.
- Lifelong dietary phenylalanine restriction to 2-6 mg/dL blood levels.
- Sapropterin (Kuvan) BH4 cofactor responsive in 20-50% of mild PKU patients.
- Large neutral amino acids (LNAA) reduce brain Phe by 40-60% as adjunct.
Newborn screening catches PKU early with high sensitivity, enabling lifelong diet treatment that prevents brain damage.
Related reading
01 · Category
Diagnosis24 stats
01
Newborn screening for PKU using tandem mass spectrometry detects Phe >2 mg/dL.
02
Guthrie bacterial inhibition assay was first used for PKU screening in 1963.
03
Universal newborn screening for PKU implemented in all 50 US states since 1966.
04
False-positive rate for PKU newborn screen is <0.05%.
05
Confirmatory test: plasma Phe >20 mg/dL confirms classic PKU.
06
BH4 loading test: 20-30 mg/kg dose reduces Phe >30% in 20-40% patients.
07
PAH gene sequencing detects mutations in 95-98% of PKU cases.
08
Prenatal diagnosis via amniocentesis for PAH mutations in at-risk pregnancies.
09
Dried blood spot Phe cutoff: >4 mg/dL prompts recall testing.
10
Tandem MS improves specificity over fluorometric methods by 99%.
11
DNA testing identifies carrier status with 99% accuracy in families.
12
Repeat heel prick at 2 weeks if initial screen borderline (2-4 mg/dL).
13
CSF neurotransmitter analysis for BH4 deficiencies in hyperphe cases.
14
Sensitivity of newborn screening for PKU is 99.7% in large cohorts.
15
Genotyping panels cover 90% common PAH mutations in Caucasians.
16
Urine pterin analysis distinguishes PAH vs BH4 defects (95% accurate).
17
High-performance liquid chromatography (HPLC) for Phe/Tyr ratio >3 flags PKU.
18
Non-invasive prenatal testing (NIPT) detects PAH mutations from maternal blood.
19
DBS dihydropteridine reductase (DHPR) activity assay screens BH4 issues.
20
Whole exome sequencing identifies rare PKU mimics in 5% cases.
21
Phe/Tyr ratio >2 in newborn screen has 98% positive predictive value.
22
Family triplet testing (parents + proband) confirms recessive inheritance.
23
96% of US newborns screened for PKU within first 48 hours.
24
Diet initiation within 7-10 days post-diagnosis prevents brain damage in 95%.
Interpretation
Diagnosis Interpretation
For the diagnosis of PKU, modern newborn screening reliably flags elevated Phe concentrations such as above 2 mg/dL with a false positive rate under 0.05%, and classic PKU is then confirmed when plasma Phe exceeds 20 mg/dL.
More related reading
02 · Category
Epidemiology30 stats
01
In the United States, the incidence of phenylketonuria (PKU) is approximately 1 in 10,000 to 15,000 live births.
02
Globally, PKU affects about 1 in 10,000 to 15,000 newborns, with variations by population.
03
In Turkey, the incidence of PKU is one of the highest worldwide at 1 in 2,605 newborns.
04
In Ireland, classical PKU incidence is 1 in 4,579 live births.
05
In Italy, the overall incidence of PKU is 1 in 13,710 newborns screened.
06
In China, PKU incidence ranges from 1 in 9,000 to 1 in 13,000 newborns.
07
In Japan, the incidence of PKU is notably low at about 1 in 120,000 births.
08
In Finland, PKU incidence is approximately 1 in 180,000 live births.
09
In the United Kingdom, PKU prevalence is around 1 in 10,000 to 14,000 newborns.
10
In Australia, newborn screening detects PKU in 1 in 10,000 infants.
11
Maternal PKU syndrome affects about 90% of untreated women with PKU who become pregnant.
12
In the US, about 300-400 babies are born with PKU annually.
13
Hyperphenylalaninemia (HPA) overall incidence is 1 in 7,313 in some European cohorts.
14
In Slovakia, PKU incidence is 1 in 9,025 newborns.
15
In Portugal, classical PKU rate is 1 in 13,111 screened newborns.
16
In Hungary, PKU incidence is 1 in 8,263 live births.
17
In the Netherlands, PKU prevalence is 1 in 18,000 newborns.
18
In Brazil, PKU incidence varies from 1 in 9,713 to 1 in 28,563.
19
In Saudi Arabia, PKU incidence is 1 in 5,000 to 6,000 births.
20
In Iran, the incidence of classic PKU is about 1 in 3,629 newborns.
21
In the US Caucasian population, PKU carrier frequency is 1 in 50.
22
In Ashkenazi Jewish populations, PKU incidence is lower at 1 in 28,000.
23
In African Americans, PKU incidence is 1 in 50,000 births.
24
Untreated PKU prevalence before screening was higher, now <1% untreated in screened countries.
25
In Qatar, PKU incidence is 1 in 5,264 newborns.
26
In Greece, PKU rate is 1 in 9,815 screened infants.
27
In Spain, classical PKU incidence is 1 in 14,177.
28
In Poland, PKU incidence is 1 in 7,418 newborns.
29
Worldwide, PKU affects over 50,000 individuals currently.
30
In the EU, newborn screening coverage for PKU is nearly 100% in most countries.
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, PKU incidence is generally rare at about 1 in 10,000 to 15,000 newborns in the US and globally, but it is markedly higher in specific populations such as Turkey at 1 in 2,605 newborns.
More related reading
03 · Category
Genetics29 stats
01
PKU is caused by mutations in the PAH gene on chromosome 12q22-q24.1.
02
Over 1,100 different mutations in the PAH gene have been identified in PKU patients.
03
The R408W mutation is the most common PAH variant, accounting for 20-30% in some populations.
04
PKU is inherited in an autosomal recessive manner requiring two mutated PAH alleles.
05
About 2% of PKU cases are due to mutations in genes other than PAH, like BH4 deficiencies.
06
The IVS12+1G>A splice mutation prevalence is high in Eastern Europe at 25-50%.
07
PAH gene spans 90 kb with 13 exons, and most mutations are missense (60%).
08
Carrier frequency for PAH mutations is 1 in 50 in Caucasians.
09
The R261Q mutation is common in Asian populations, frequency up to 30%.
10
Large deletions/duplications account for 5% of PAH mutations.
11
Genotype-phenotype correlation exists; e.g., null mutations lead to classic PKU.
12
In 98% of cases, PAH deficiency causes PKU; 2% are tetrahydrobiopterin (BH4) variants.
13
The most frequent mutation in Turkey is IVS10-11G>A at 26.8%.
14
PAH gene has over 2,000 reported variants in the PAHdb database.
15
Compound heterozygosity for PAH mutations occurs in 60-70% of patients.
16
Promoter mutations in PAH are rare, less than 1% of cases.
17
In Chinese patients, R243Q mutation frequency is 17.5%.
18
Splice site mutations comprise 20-25% of PAH alterations.
19
Homozygous R408W in Polish patients leads to severe phenotype.
20
BH4-responsive PKU is linked to specific PAH mutations like A300S (40% response).
21
PAH nonsense mutations result in 30% truncated protein.
22
Frameshift mutations in PAH exon 12 are pathogenic in 5% cases.
23
Mediterranean populations have high L48S mutation frequency.
24
PAHdb database logs 1,946 mutations as of 2020.
25
D338Y mutation correlates with mild HPA phenotype.
26
Untreated classic PKU patients have blood phenylalanine >20 mg/dL.
27
Mild PKU defined by Phe levels 10-20 mg/dL untreated.
28
Intellectual disability in untreated PKU affects 95% of patients.
29
Microcephaly occurs in 70-80% of untreated classic PKU cases.
Interpretation
Genetics Interpretation
Genetically, classical PKU is driven by mutations in the PAH gene on chromosome 12q22-q24.1 with over 1,100 variants known, yet a single hotspot like the R408W mutation can account for 20 to 30% in some populations, while other genetic causes make up about 2% of cases and a specific splice change reaches 25 to 50% prevalence in Eastern Europe.
More related reading
04 · Category
Symptoms20 stats
01
Musty odor in urine/sweat due to phenylacetate in 75% untreated.
02
Eczematous rash seen in 20-30% of untreated infants with PKU.
03
Seizures develop in 25% of untreated adolescents/adults with PKU.
04
Behavioral problems like hyperactivity in 60% of early-treated but off-diet adults.
05
Hypopigmentation: fair skin/hair in 90% untreated due to Phe competing with Tyr.
06
Tremor and ataxia in 50% of untreated adults over 30 years.
07
IQ drops by 5 points per 1 mg/dL Phe increase above 6 mg/dL in treated.
08
Maternal PKU: 73% microcephaly in offspring if Phe >20 mg/dL preconception.
09
Cardiac abnormalities in 15-20% untreated PKU adults.
10
Anxiety/depression in 40% of early-treated PKU adults.
11
Growth retardation in 25% untreated children.
12
Enamel hypoplasia in 50% of permanent teeth in poorly controlled PKU.
13
Executive function deficits persist in 75% of treated patients.
14
Spasticity in 30% of untreated late-diagnosed PKU.
15
Vomiting and irritability in first months in 40% undiagnosed infants.
16
ADHD-like symptoms in 50% of adolescents with poor metabolic control.
17
Osteoporosis risk 3-fold higher in adults with PKU off-diet.
18
White matter abnormalities on MRI in 25% early-treated patients.
19
Fatigue and sleep disturbances in 35% of treated adults.
20
Congenital heart defects in 12% of maternal PKU offspring.
Interpretation
Symptoms Interpretation
In the symptoms category for untreated PKU, musty odor appears in 75% and neurologic and behavioral effects are common, with seizures in 25% of adolescents or adults and tremor or ataxia in 50% of those over 30, showing that delays in dietary treatment often translate into multiple, high frequency, systemic symptoms.
More related reading
05 · Category
Treatment22 stats
01
Lifelong dietary phenylalanine restriction to 2-6 mg/dL blood levels.
02
Sapropterin (Kuvan) BH4 cofactor responsive in 20-50% of mild PKU patients.
03
Large neutral amino acids (LNAA) reduce brain Phe by 40-60% as adjunct.
04
Pegvaliase (Palynziq) enzyme substitution lowers Phe 60-80% in adults.
05
Early treatment (<3 weeks) yields IQ >85 in 90% classic PKU cases.
06
Maternal PKU diet preconception reduces offspring defects to <5%.
07
Phe monitoring frequency: weekly in infants, monthly in stable patients.
08
Medical foods provide 70-90% protein needs in PKU formula.
09
Target blood Phe: 2-6 mg/dL (120-360 µmol/L) per ACMG guidelines.
10
LNAA therapy improves executive function scores by 15-20%.
11
Pegvaliase injection weekly sustains Phe <10 mg/dL in 60% patients.
12
Transition to adult care improves control in 75% with structured programs.
13
Glycomacropeptide (GMP) low-Phe foods tolerated better than AA mixes.
14
BH4 loading predicts responsiveness; sustained dose 10-20 mg/kg/day.
15
Liver transplant rare, normalizes Phe in <10 cases reported.
16
Adherence rates 50-70% in adolescents; improves with education.
17
Gene therapy trials (e.g., AAV-PAH) show 30% Phe reduction in animals.
18
Off-diet after age 10 leads to 10-15 IQ point loss over 10 years.
19
Multidisciplinary clinics improve metabolic control by 25%.
20
Pegvaliase anaphylaxis risk 10-20%, managed with desensitization.
21
Newborn diet starts day 7-10, Phe tolerance 20-40 mg/kg/day infants.
22
Long-term BH4 monotherapy maintains Phe <360 µmol/L in 30%.
Interpretation
Treatment Interpretation
Under treatment, the main trend is that targeted interventions can markedly lower blood and brain phenylalanine, from keeping Phe at 2 to 6 mg/dL lifelong and reducing it by 60 to 80% with pegvaliase in adults to delivering the best outcomes when therapy starts within 3 weeks, with IQ over 85 in 90% of classic PKU cases.
report visual · Comparison
How well PKU screening catches it—and what false alarms look like
Newborn screening for PKU shows very high sensitivity, while the false-positive rate stays low.
Sensitivity of newborn screening for PKU is 99.7% in large cohorts.99.7%
Newborn screening for PKU using tandem mass spectrometry detects Phe >2 mg/dL.
2
False-positive rate for PKU newborn screen is <0.05%.
0.05%
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Karl Becker. (2026, February 13). Pku Statistics. Gitnux. https://gitnux.org/pku-statistics
MLA
Karl Becker. "Pku Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pku-statistics.
Chicago
Karl Becker. 2026. "Pku Statistics." Gitnux. https://gitnux.org/pku-statistics.
Sources & references
11 datasets cited across this report · attribution is report-level